Clinical Trials Browser

Phase 2 × pazopanib × Breast × Clear all

Breast Neoplasms, Neoplasms

NCT01392352 2020-02-13

HYPAZ

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Hypertension, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT00509587 2018-08-08

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase 2 Completed

21 enrolled 10 charts

Breast

Breast Neoplasms

NCT01394211 2018-07-26

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Phase 2 Terminated

2 enrolled 3 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00615524 2018-01-12

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00347919 2016-02-25

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Phase 2 Completed

189 enrolled 15 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00849472 2014-03-04

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Phase 2 Completed

101 enrolled 16 charts

Breast

Breast Neoplasms

NCT00558103 2013-02-04

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Phase 2 Completed

163 enrolled 14 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Clinical Trials

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

HYPAZ

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer